Researchers at NDORMS have studied the association between ambulatory COVID-19 and short-term risk of venal thrombosis and the clinical and genetic risk factors predisposing them to developing post–COVID-19 thrombosis.
Aug 22, 2022
0
63
A new study published in The Lancet Psychiatry from the University of Oxford and the National Institute for Health and Care Research (NIHR) Oxford Health Biomedical Research Centre investigated neurological and psychiatric ...
Aug 17, 2022
0
100
Understanding which cells give rise to which areas of cancer can improve our understanding of how a tumor has grown and developed, including how it has changed genetically over time. This has been made possible using a new ...
Aug 10, 2022
0
41
Clinical researchers from Oxford University's Department of Psychiatry and Oxford Health NHS Foundation Trust, together with colleagues from elsewhere, have developed guidance to help clinicians identify and treat patients ...
Aug 8, 2022
0
10
A revolutionary new hand prosthesis powered and controlled by the user's breathing has been developed by researchers at the University of Oxford.
Jul 29, 2022
0
3
Researchers from the University of Oxford have today reported new findings from a Phase 1 clinical trial studying the immune response and safety of their newly-developed single shot rabies vaccine, ChAdOx2 RabG—with promising ...
Jul 28, 2022
0
101
The short-term effects of excessive drinking are well known, but to date it has been less certain whether alcohol also accelerates the aging process.
Jul 26, 2022
0
241
A new NDORMS study, published in The Lancet Rheumatology, has found a genetic variant that increases the risk of both carpal tunnel syndrome and trigger finger, and opens the door for new therapies that involve blocking the ...
Jul 22, 2022
0
96
Over a quarter (26.5%) of children reported trying to lose weight between 2015 and 2016, a 5% increase over 1997 and 1998, finds new research from the University of Oxford. The largest increases in weight loss attempts were ...
Jul 18, 2022
0
67
Two drugs, eszopiclone and lemborexant—both not currently licensed for the treatment of insomnia in the UK—were shown to perform better than others, both in the acute and long-term treatment of insomnia in adults, according ...
Jul 15, 2022
0
82
